Novo Nordisk Science
For US Healthcare Professionals
The presentations below were developed by Novo Nordisk Inc. and must be viewed with the provided source publication that is the subject of the corresponding presentation.
Wegovy® injection
Disclosures and Firm-Generated Presentation
Source Publication: Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials
Source Publication: Effects of semaglutide in obesity‐related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP‐HFpEF programme
Wegovy® Prescribing Information
Disclosures and Firm-Generated Presentation
Source Publication: Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
Wegovy® Prescribing Information
Wegovy® tablet / Ozempic® tablet
Disclosures and Firm-Generated Presentation
Source Publication: Efficacy and safety of once-daily oral semaglutide 25mg and 50mg compared with 14mg in adults with type 2 diabetes
Wegovy® Prescribing Information
Ozempic® tablet Prescribing Information
NovoSeven® RT
Disclosures
The Use of Recombinant Activated Factor VII in Patients with Glanzmann's Thrombasthenia
NovoSeven® RT Prescribing Information